금융 뉴스 허브

Nvidia in talks to buy ‘open’ model startup Reflection AI: FT

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.

Cliffs unit is said to proceed with Canada layoffs despite govt. ultimatum

Wall Street split on pioneering S&P 500 stock's price target

Wall Street analysts are split on the outlook of a stock that joined the S&P 500 only last year.

China passenger vehicle retail market slumps 24% in September

Dell (DELL) Has Outpaced the S&P 500 by a Wide Stretch. Will the AI-Fueled Run Continue?

Much of the recent growth for Dell Technologies Inc. (NYSE:DELL) has come through hardware sales, which is a lower-margin, high-volume avenue for the overall business. Bottom-line expansion in the fut ...

Warren Buffett warns of a reality check coming for stock investors

Warren Buffett has a name for what is happening in markets right now. Investors may want to hear it.

Flight disruptions growing after missile attack on Saudi airport

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Philips investors’ move to probe company over 2021 recall denied by Dutch court

Real estate stocks outperform broader markets

Palantir Stock Closed at a Record After Barclays Set a $265 Target. Here’s What Q3 Has to Clear

Key Stats for Palantir StockCurrent Price: $209. 05Target Price (Mid): ~$1,495Street Target: ~$201Potential Total Return: ~615%Annualized IRR: ~59% / yearWhat Happened?Palantir Technologies (PLTR) clo ...